Bone Marrow Transplant Denied by Insurance? How to Appeal an SCT Denial

Hematopoietic stem cell transplantation (HSCT) — commonly called bone marrow transplant or stem cell transplant (SCT) — is a potentially curative treatment for blood cancers, bone marrow failure syndromes, and certain immune deficiencies. Insurance denials for SCT are common, expensive to contest, and can be literally fatal if not resolved quickly. This guide explains the key clinical and legal arguments for appealing an SCT denial.

Allogeneic vs. Autologous SCT: Why It Matters

The type of transplant matters significantly for both clinical outcomes and insurance coverage:

Autologous SCT: The patient's own stem cells are collected, stored, and reinfused after high-dose conditioning chemotherapy. Primarily used for multiple myeloma, certain lymphomas (Hodgkin and non-Hodgkin), and some solid tumors. Lower rejection risk, no donor matching required, but no graft-vs.-tumor effect.

Allogeneic SCT: Stem cells are obtained from a matched donor (sibling, unrelated matched donor, cord blood, haploidentical). Provides graft-vs.-leukemia (GVL) or graft-vs.-tumor effect. Used for AML, ALL, MDS, aplastic anemia, and other conditions. Higher complexity, requires donor matching, graft-versus-host disease (GVHD) risk.

Insurers apply different coverage criteria to autologous and allogeneic SCT. Allogeneic SCT for non-standard indications is more commonly denied. Your appeal should clearly specify the type of transplant proposed and cite the diagnosis-specific guideline supporting it.

Common Diagnoses and Standard-of-Care Status

For the following diagnoses, SCT is well-established standard of care and denials are strongly challengeable:

• Acute Myeloid Leukemia (AML): Allogeneic SCT in first or second complete remission, particularly for intermediate and high-risk cytogenetics
• Acute Lymphoblastic Leukemia (ALL): Allogeneic SCT in high-risk or relapsed/refractory disease
• Multiple Myeloma: Autologous SCT following induction therapy
• Hodgkin Lymphoma (refractory/relapsed): Autologous SCT after second-line chemotherapy
• Non-Hodgkin Lymphoma (relapsed/refractory DLBCL, MCL, others): Autologous or allogeneic SCT depending on subtype
• Myelodysplastic Syndrome (MDS): Allogeneic SCT for intermediate-2 or high-risk MDS
• Aplastic Anemia: Allogeneic SCT for severe aplastic anemia (SAA), particularly in younger patients

For these indications, denial is inconsistent with NCCN Guidelines, ASH guidelines, and standard oncology practice.

Conditioning Regimen and Coverage

The conditioning regimen (preparative regimen) is the high-dose chemotherapy and/or radiation administered immediately before stem cell infusion to eradicate disease and create space in the bone marrow. Conditioning regimens are an integral part of the SCT procedure, not separately deniable components.

Insurers sometimes deny specific conditioning drugs as "experimental" or attempt to limit coverage to the transplant procedure itself without the conditioning. Challenge this framing: no transplant is clinically possible or safe without an appropriate conditioning regimen, and the conditioning drugs used are standard oncology agents.

Reduced-intensity conditioning (RIC) and non-myeloablative conditioning are used for older patients or those with comorbidities who cannot tolerate full myeloablative conditioning. If the insurer denies RIC on the grounds that it is less established, cite current NCCN and ASH guidelines endorsing RIC in appropriate patient populations.

Donor Matching and Coverage for Donor Costs

For allogeneic SCT, donor search, typing, and collection costs are typically covered by the recipient's insurance under the National Bone Marrow Donor Program framework. Ensure your insurer has authorized:

• HLA typing of potential sibling donors
• National Marrow Donor Program (NMDP)/Be The Match registry search
• Donor evaluation and stem cell collection costs
• Cord blood unit acquisition if applicable

BMT Center Requirements

Insurers frequently require SCT to be performed at a FACT-accredited (Foundation for the Accreditation of Cellular Therapy) transplant center. If your proposed center is FACT-accredited and your insurer directs you elsewhere, document your center's accreditation status and appeal the network requirement.

If no FACT-accredited center is in-network in your region, request a single-case agreement with your proposed center.

Building the Appeal

Step 1: Cite NCCN Guidelines (category 1 recommendations for your diagnosis and SCT indication) directly in the appeal letter.

Step 2: Have your hematologist-oncologist and the SCT attending document the specific disease characteristics that make SCT standard of care — cytogenetics, disease response, molecular markers.

Step 3: Address the conditioning regimen as integral to the procedure.

Step 4: Document FACT accreditation of your transplant center.

Step 5: Request expedited review — blood cancers can relapse rapidly, and delay in SCT has direct survival consequences.

Fight Back With ClaimBack

SCT denials are among the highest-stakes insurance disputes. ClaimBack helps patients with hematologic malignancies and bone marrow failure build compelling, evidence-based appeals to get life-saving treatment covered.

Start your appeal with ClaimBack

Related Reading

• What Is Medical Necessity?
• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeal: Which to File